Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | SWI:SNF matrix associated | 0.1122 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.1122 | 1 | 0.5 |
Plasmodium vivax | hypothetical protein, conserved | 0.1122 | 1 | 0.5 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.1122 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.1122 | 1 | 0.5 |
Onchocerca volvulus | 0.1122 | 1 | 0.5 | |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.1122 | 1 | 1 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.1122 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.1122 | 1 | 0.5 |
Chlamydia trachomatis | DNA topoisomerase I | 0.1122 | 1 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.1122 | 1 | 0.5 |
Schistosoma mansoni | brg-1 associated factor | 0.1122 | 1 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.1122 | 1 | 0.5 |
Chlamydia trachomatis | SWIB complex protein | 0.1122 | 1 | 0.5 |
Brugia malayi | brahma associated protein 60 kDa | 0.1122 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.1122 | 1 | 0.5 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.1122 | 1 | 1 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.1122 | 1 | 1 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.1122 | 1 | 0.5 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.1122 | 1 | 0.5 |
Loa Loa (eye worm) | brahma associated protein | 0.1122 | 1 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.1122 | 1 | 0.5 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.1122 | 1 | 0.5 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.1122 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.